Back to results
US 7,524,633 B2Granted
Method of detection of prostate cancer
AssigneeThe Johns Hopkins University School of Medicine
InventorDavid Sidransky
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and kits useful for detecting neplasia by measuring the methylation level of biomarkers, especially the promoter region of GSTP1 for the detection of prostate adenocarcinoma.
Claims35
A method for determining an increased likelihood of early stage prostate neoplasia comprising:
- determining a methylation ratio of a tissue sample from a subject, wherein the methylation ratio is the level of methylation of a bisulfite-treated promoter region of glutathione-S-transferase (GSTP 1) relative to a level of bisulfite-treated DNA copy number of a reference gene, wherein a methylation ratio higher than the methylation ratio in tissue from a normal subject is indicative of an increased likelihood of early stage prostate neoplasia in the subject.
A method for determining an increased likelihood of early stage prostate adenocarcinoma comprising
- determining the methylation level of a promoter region of glutathione-S-transferase (GSTP1) in a sample of bodily fluid from a subject, wherein the methylation level is determined using a conventional polymerase chain reaction (PCR), or real-time PCR and wherein a methylation level higher than the methylation level in a normal subject is indicative of an increased likelihood of early stage prostate neoplasia in the subject.
A method for determining an increased likelihood of early stage prostate adenocarcinoma comprising
- amplifying a promoter region of glutathion-S-transferase (GSTP 1) in a biological sample from a subject by means of oligonucleotide primers in the presence of at least one specific oligonucleotide probes,
- wherein the promoter region is modified by an agent that modifies unmethylated cytosine to produce a converted nucleic acid, and
- wherein at least one oligonucleotide primer or specific oligonucleotide probe is capable of distinguishing between unmethylated and methylated nucleic acid,
- determining the methylation level of the promoter region by determining the amplification level of the promoter region based on amplification-mediated displacement of the specific oligonucleotide probe,
- wherein a methylation level higher than the methylation level in a normal subject is indicative of an increased likelihood of early stage prostate adenocarcinoma in the subject.
2 more elements
Dependencies are inferred from the claim text.